Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism

4Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Background: Amniotic fluid embolism (AFE) is a rare cause of severe maternal morbidity and mortality. No well-studied protocols are available for management of AFE. We present a case of cardiac arrest secondary to presumed AFE and the use of atropine-ondansetron-ketorolac (AOK). Case Report: A 34-year-old gravida 4, para 2012 underwent a repeat cesarean section at 39 weeks of gestation. After delivery of the placenta, hypoxia and hypotension developed, followed by cardiac arrest. Protocols for management of maternal cardiac arrest were followed. Echocardiogram demonstrated right ventricular dilation and hypokinesis. AOK was administrated during prolonged cardiac arrest, and spontaneous circulation returned. The patient was extubated on postoperative day 3 and discharged on postoperative day 10 without neurologic deficits. Conclusion: Management of AFE should include consideration of the addition of AOK to typical guidelines.

Cite

CITATION STYLE

APA

Long, M., Martin, J., & Biggio, J. (2022). Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism. Ochsner Journal, 22(3), 253–257. https://doi.org/10.31486/toj.21.0107

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free